- Home
- BEAM vs EFSC Comparison
BEAM vs EFSC Comparison
Compare BEAM & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEAM | EFSC |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | 1256 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BEAM | EFSC |
|---|---|---|
| Price | $26.65 | $56.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | $48.09 | ★ $65.67 |
| AVG Volume (30 Days) | ★ 2.0M | 147.3K |
| Earning Date | 11-04-2025 | 01-26-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | N/A | ★ 8.68 |
| EPS | N/A | ★ 5.13 |
| Revenue | $55,701,000.00 | ★ $646,694,000.00 |
| Revenue This Year | N/A | $20.14 |
| Revenue Next Year | $26.52 | $5.15 |
| P/E Ratio | ★ N/A | $11.06 |
| Revenue Growth | N/A | ★ 9.31 |
| 52 Week Low | $13.53 | $45.22 |
| 52 Week High | $35.25 | $62.60 |
Technical Indicators
Market Signals| Indicator | BEAM | EFSC |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 58.02 |
| Support Level | $25.86 | $56.13 |
| Resistance Level | $28.10 | $58.25 |
| Average True Range (ATR) | 1.56 | 1.25 |
| MACD | 0.17 | 0.22 |
| Stochastic Oscillator | 57.47 | 58.58 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.